Low toxicity with SAVI breast brachytherapy

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 3
Volume 17
Issue 3

Using the SAVI applicator for breast brachytherapy, 14 of 18 patients experienced no skin reactions, and the other four had only minor reactions that resolved quickly, Constantine Mantz, MD, reported at the 25th Annual Miami Breast Cancer Conference. Dr. Mantz, a radiation oncologist at 21st Century Oncology, Inc. Fort Myers, Florida, said that the overall cosmetic outcomes with SAVI were rated excellent.

ORLANDO-Using the SAVI applicator for breast brachytherapy, 14 of 18 patients experienced no skin reactions, and the other four had only minor reactions that resolved quickly, Constantine Mantz, MD, reported at the 25th Annual Miami Breast Cancer Conference. Dr. Mantz, a radiation oncologist at 21st Century Oncology, Inc. Fort Myers, Florida, said that the overall cosmetic outcomes with SAVI were rated excellent.

SAVI, made by Cianna Medical Inc., is a single-entry, multicatheter device. It is the only accelerated partial breast irradiation single-entry device that can customize the dose according to patient-specific anatomy, Dr. Mantz said.

He noted that nearly 60% of patients in the study had tumors located close to the skin surface, a location that excluded them from treatment with balloon brachytherapy

Recent Videos
Data from the SPOTLIGHT and GLOW trials reveal that zolbetuximab increased survival in patients with CLDN18.2-positive gastric or GEJ adenocarcinoma.
The incorporation of zolbetuximab in addition to chemotherapy has shown benefit in patients with Claudin 18.2–positive gastric cancers in clinical trials.
Michael J. Hall, MD, MS, FASCO, discusses the need to reduce barriers to care for those with Li-Fraumeni syndrome, including those who live in rural areas.
Patrick Oh, MD, highlights next steps for further research in treating patients with systemic therapy in addition to radiotherapy for early-stage NSCLC.
The ability of metformin to disrupt mitochondrial metabolism may help mitigate the risk of cancer in patients with Li-Fraumeni syndrome.
Related Content